Strategic partnerships Target healthcare providers and hospital networks expanding cardio-oncology programs, focusing on MyoStrain integration with existing oncology workflows, to capture corporate license deals and regional deployments (e.g., Spain with Vithas Group) and grow enterprise footprint.

Regulatory momentum Leverage FDA-510(k) clearance and EU CE certification to approach hospitals and clinics seeking compliant, non-invasive cardiac monitoring solutions for cancer patients undergoing cardiotoxicity risk management.

Expanded clinical use Promote MyoStrain 6.1 and future iterations as standard of care for early cardiotoxicity detection, emphasizing rapid 10-minute tests and MyoHealth Score to drive adoption in cardio-oncology clinics and imaging centers.

Global expansion Capitalize on recent international activity and CE/EU market readiness by pursuing partnerships and distributed sales in Europe, leveraging existing launches and hospital collaborations to accelerate cross-border selling.

Evidence-driven selling Highlight the extensive clinical research footprint and 400+ publications to support ROI-focused conversations with administrators, showcasing improved patient management, potential cost savings, and alignment with cancer care quality metrics.